"Charting a new course for prostate cancer" - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer - Abstract

Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer.

A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer.

Written by:
Voskoboynik M, Staffurth J, Malik Z, Sweeney C, Chowdhury S.   Are you the author?
Department of Medical Oncology, Guy's Hospital, Great Maze Pond, London, UK.

Reference: Expert Rev Anticancer Ther. 2014 Nov;14(11):1253-6.
doi: 10.1586/14737140.2014.971112


PubMed Abstract
PMID: 25353342

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe